MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s11748-018-01054-7

Медицинская библиотека · General thoracic and cardiovascular surgery · 2019

Multimodality therapy for thymoma patients with pleural dissemination.

Nakamura Shota, Kawaguchi Koji, Fukui Takayuki, Hakiri Shuhei, Ozeki Naoki, Mori Shunsuke, Goto Masaki, Hashimoto Kumiko, Ito Toshinari, Yokoi Kohei

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Although multidisciplinary treatment is recommended for patients with advanced stage and recurrent thymoma, a detailed treatment strategy remains controversial. We have performed a multimodality therapy of induction chemotherapy (CAMP therapy: cisplatin, doxorubicin, and methylprednisolone) combined with surgery for those patients. We now conducted a retrospective study for investigating the results of this multimodality therapy for thymoma patients with pleural dissemination.

PATIENTS AND

METHODS

Between 2003 and 2017, 201 patients underwent surgical resection for thymomas. Twenty-six of them received induction CAMP therapy followed by surgery, and 19 of them with pleural dissemination were enrolled in this study. Those cohort were divided into 2 groups by employing surgical procedures: extrapleural pneumonectomy (EPP) group (n = 10) and resection of plural dissemination (RPD) group (n = 9).

RESULTS

The median age of all patients was 49 years. Based on the WHO classification, the histological diagnoses of those thymomas were as follows: Type B1 (n = 1), Type B2 (n = 13), and Type B3 (n = 5). Seven patients were complicated with myasthenia gravis (MG). Clinical stage of the 13 primary cases based on the Masaoka classification were stage IV, and the remaining six cases had recurrent pleural dissemination after surgery. Partial response in induction CAMP therapy was obtained in 78.9% (n = 15) of the patients. Adverse events (Grade 4) occurred in 2 patients (10.5%). Postoperative complications (Grade 4) were observed in 2 patients (10.5%). In all of the enrolled patients, the five-year overall survival rate (5Y-OS) and 5-year progression-free survival rate (5Y-PFS) were 76.7% and 55.1%, respectively. In the EPP group, 5Y-OS and 5Y-PFS were 83.3% and 83.3%, respectively, and in the RPD group, 70.0% and 29.6%, respectively.

CONCLUSIONS

Multidisciplinary treatment using induction CAMP therapy and surgical resection for thymoma patients with pleural dissemination was effective and feasible. Because of the low recurrent rate of disease, young patients with good cardiopulmonary function and well-controlled MG might be good candidates for EPP.

Для цитирования: Nakamura Shota, Kawaguchi Koji, Fukui Takayuki, Hakiri Shuhei, Ozeki Naoki, Mori Shunsuke, Goto Masaki, Hashimoto Kumiko, Ito Toshinari, Yokoi Kohei. Multimodality therapy for thymoma patients with pleural dissemination.. General thoracic and cardiovascular surgery. 2019. DOI: 10.1007/s11748-018-01054-7.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.